CSHL 2022 Mechanisms & Models of Cancer Conference

CSHL 2022 机制

基本信息

  • 批准号:
    10536252
  • 负责人:
  • 金额:
    $ 0.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

COLD SPRING HARBOR LABORATORY CONFERENCE MECHANISMS AND MODELS OF CANCER August 16 - 20, 2022 Recent years have produced transformative discoveries that have revealed the mechanisms behind the development and progression of cancer, both from the perspective of the cancer cell and the host response. These advances have resulted in targeted cancer therapies that have extended patient survival, as well as new immune-based therapies that have, in select cases, resulted in cures of previously intractable malignancies. Stunning technological developments have enabled us to interrogate the cancer genome and epigenome with unprecedented depth and sophistication, uncovering the challenges that tumor heterogeneity imposes for cancer therapy, while also enabling more accurate therapeutic monitoring. Advances in functional genomic technologies allow us to turn oncogenes and tumor suppressor genes on an off at will in vitro and in vivo to determine their function. More robust tumor models, such as organoids, have been developed, revealing new insights into cancer cell biology, while enabling the rapid identification and testing of new therapeutics. With advances in structural biology, we can examine the three-dimensional structure of oncogenic proteins and protein complexes, facilitating development of small molecule inhibitors or antagonistic antibodies. Powerful strategies also allow us to interrogate how metabolic reprogramming in cancer cells, opening up the possibility of novel therapeutic approaches that exploit metabolic vulnerabilities. Improvements in computational biology are yielding new insights into biological networks and tumor evolution. Dissemination and use of these technologies, models and mechanism-based approaches in this fast-moving field is greatly facilitated by meetings that bring investigators together to present and openly discuss their latest unpublished research findings. We also need to train the next generation of leaders in the field, and an essential part of this process is this fantastic opportunity for young investigators, such as graduate students and postdocs, to present their work and interact one-on-one with senior investigators. The Mechanisms and Models of Cancer meeting at Cold Spring Harbor Laboratory (CSHL) is one of the premier vehicles for promoting the next intellectual leaps in cancer research and propelling the field into the future to the benefit of cancer patients. The precise scope of the individual sessions will be decided on the basis of the openly submitted abstracts. Each session will be chaired by two established scientists in the field, who will establish the format of each session based on submitted abstracts. The chairs will introduce and give an overview of the topics in their sessions and a brief update on their own research. Particular emphasis will be given to promoting the active participation of graduate students, postdoctoral fellows and new investigators, as well as of leading scientists in the field. Two leading experts in diverse areas of cancer biology will deliver keynote addresses during the conference, and there will also be a “legacy lecture” by a major luminary in the field. It is anticipated that the meeting will provide unique opportunities for the exchange of data and ideas by both junior and senior investigators in different areas of research as they apply to cancer genetics and tumor suppressor genes. Given the success of past meetings held at CSHL on this topic between 1996 and 2020, we anticipate the attendance of about 400 scientists from laboratories around the world.
冷泉港实验室会议 癌症的机制和模型 2022年8月16日至20日 近年来已经产生了变革性的发现,揭示了背后的机制 从癌细胞和宿主的角度来看癌症的发展和进展 反应这些进展导致了靶向癌症治疗,延长了患者的生存期, 以及新的基于免疫的疗法,在某些情况下, 顽固性恶性肿瘤令人惊叹的技术发展使我们能够审问癌症 基因组和表观基因组以前所未有的深度和复杂性,揭示了挑战, 肿瘤异质性为癌症治疗带来了新的挑战,同时也使更准确的治疗监测成为可能。 功能基因组技术的进步使我们能够启动癌基因和抑癌基因 在体外和体内随意关闭,以确定其功能。更强大的肿瘤模型,如类器官, 揭示了对癌细胞生物学的新见解,同时能够快速识别 和新疗法的测试。随着结构生物学的进步,我们可以检查三维 致癌蛋白和蛋白复合物的结构,促进小分子抑制剂的开发 或拮抗性抗体。强有力的策略也使我们能够询问代谢重编程是如何在细胞内发生的。 癌细胞,开辟了新的治疗方法的可能性,利用代谢 漏洞计算生物学的进步正在产生对生物网络的新见解, 肿瘤演变传播和使用这些技术、模型和基于机制的方法 在这个快速发展的领域,会议极大地促进了调查人员的交流, 公开讨论他们最新的未发表的研究成果。我们还需要培养下一代 这个过程的一个重要部分是给年轻的研究人员提供了一个绝佳的机会, 例如研究生和博士后,来展示他们的工作,并与高级研究人员进行一对一的互动 investigators.在冷泉港实验室(CSHL)召开的癌症机制和模型会议是 这是促进癌症研究下一次智力飞跃和推动癌症研究的主要工具之一。 为癌症患者造福。个别会议的确切范围将是 根据公开提交的摘要决定。每届会议将由两名常设 该领域的科学家,他们将根据提交的摘要确定每次会议的形式。的 主席将介绍和概述其会议的主题,并简要介绍最新情况 research.将特别强调促进研究生的积极参与, 博士后研究员和新的研究人员,以及该领域的领先科学家。两名顶尖专家 在癌症生物学的不同领域将在会议期间发表主旨演讲, 成为该领域一位重要人物的"遗产讲座"。预计会议将提供独特的 初级和高级调查人员在不同领域交流数据和想法的机会, 癌症遗传学和肿瘤抑制基因的研究。鉴于过去的成功 在1996年至2020年期间,CSHL就这一主题举行了多次会议,我们预计约有400人出席 来自世界各地实验室的科学家。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID J. STEWART其他文献

DAVID J. STEWART的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID J. STEWART', 18)}}的其他基金

CSHL Single Cell Analysis Course (2023-2027)
CSHL单细胞分析课程(2023-2027)
  • 批准号:
    10627446
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Eukaryotic DNA Replication and Genome Maintenance Conference
CSHL 2023真核DNA复制与基因组维护会议
  • 批准号:
    10677192
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Eukaryotic mRNA Processing Conference
CSHL 2023真核mRNA加工会议
  • 批准号:
    10679367
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Conference on Biology of Cancer: Microenvironment & Metastasis
CSHL 2023癌症生物学会议:微环境
  • 批准号:
    10750261
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Brain Barriers Conference
CSHL 2023脑障碍会议
  • 批准号:
    10608583
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Mechanisms of Metabolic Signaling Conference
CSHL 2023代谢信号机制会议
  • 批准号:
    10751346
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Neurobiology of Drosophila Conference
CSHL 2023果蝇神经生物学会议
  • 批准号:
    10669936
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Conference on Microbial Pathogenesis & Host Response
CSHL 2023微生物发病机制会议
  • 批准号:
    10675902
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL The Biology of Genomes Conference (2023-2027)
CSHL基因组生物学会议(2023-2027)
  • 批准号:
    10608266
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
CSHL 2023 Conference on Telomeres & Telomerase
CSHL 2023端粒会议
  • 批准号:
    10671999
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 0.75万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 0.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了